Rational Vaccines is developing a new line of therapeutic HSV vaccines.
TheravaxHSV-1 and TheravaxHSV-2 are based on live-attenuated HSV ICP0– mutant viruses, which may be used to safely vaccinate recipients with >99% of HSV’s foreign protein signature. Phase 1 trials of the TheravaxHSV-2 vaccine are imminent. If the TheravaxHSV-2 vaccine proves safe and effective in reducing the symptoms of herpes sufferers, similar trials of the TheravaxHSV-1 vaccine will be conducted. Learn more about how TheravaxHSV vaccines may help herpes sufferers achieve a better standard of care.